ABSTRACT
Umbilical cord blood (UCB) is an alternative source for hematopoietic stem cells allogeneic hematopoietic stem cell transplantation in the absence of compatible donor. UCB transplantation has a lower incidence of chronic graft versus host disease (GvHD) but is associated with slower engraftment and slower immune reconstitution as compared to other sources. Dendritic cells (DC) and Natural Killer cells (NK) play a central role in the development of GVHD, the graft versus leukemia (GvL) effect, and in the control of infectious complications. We quantified by multiparametric flow cytometry monocytes, lymphocytes, NK cells, and DC, including their subsets, in UCB samples from 54 healthy newborns and peripheral blood (PB) from 25 healthy adult volunteers. In the UCB samples, there were higher counts of CD56brightCD16-NK cells (median 0.024×109/L), as compared to the PB samples (0.012×109/L, P<0.0001), CD56dimCD16bright NK cells (median 0.446×109/L vs. 0.259×109/L for PB samples, P= 0.001), and plasmacytoid dendritic cells (pDC, median 0.008×109/L for UCB samples vs. 0.006×109/L for PB samples, P= 0.03). Moreover, non-classical monocytes counts were lower in UCB than in PB (median 0.024×109/L vs. 0.051 x109/L, respectively, P< 0.0001). In conclusion, there were higher counts of NK cells and pDC, and lower counts of non-classical monocytes in UCB than in PB from healthy individuals. These findings might explain the lower incidence and severity of chronic GVHD although maintaining the GVL effect in UCB transplants recipients as compared to other stem cell sources.
Highlights
CD56brightCD16- NK cells are more frequent in UCB than in PB.
Plasmacytoid dendritic cells are more frequent in UCB than in PB.
Non-classical monocytes are more frequent in PB than in UCB.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.C.R.B. was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES, no. 001. V.C.M. was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq process no. 1415752018- 2.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics: - Unifesp: "Comite de etica em pesquisa da Universidade Federal de Sao Paulo" - Final decision "approved" - Hospital Amaro Maternal: "Comite de etica em pesquisa" - Final decision "approved"
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is available in our database.
